# Triple W Japan K.K.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/triple-w-japan-k-k

- Industry: Healthcare IT
- Headquarters: Tokyo, Japan
- Website: www-biz.co
- Total disclosed funding: $18M
- Latest round: Series D (Mar 17, 2023)
- Investors on record: 7

## About

Triple W Japan K.K., based in Tokyo, specializes in innovative solutions for managing urinary health, primarily through its DFree product line that enhances users' quality of life by providing timely restroom notifications.Founded in 2015 in Tokyo, Japan, Triple W Japan K.K. focuses on developing assistive technologies for urinary health. The company has completed a total of 8 deals, with the latest funding round occurring on March 17, 2023. The CEO, AT Nakanishi, leads the company as it continues to innovate in the healthcare space. The company raised JPY 637 million in VENTURE DEBT during its most recent funding round, contributing to a total amount raised of JPY 637 million.Triple W Japan K.K. offers innovative products, including the DFree Personal and DFree Professional services, aimed at managing urinary health. The DFree Personal device alerts users when they need to use the restroom, improving their quality of life. Additionally, the DFree Professional service assists healthcare institutions by managing patient data via an application, enhancing efficiency in care delivery.Triple W Japan K.K. generates revenue through a subscription-based model and direct sales. The DFree Personal device is sold to individual users, while healthcare providers subscribe to the DFree Professional platform for ongoing access to data management tools. This structure ensures a recurring revenue stream from both individual consumers and institutional clients.In March 2023, Triple W Japan K.K. secured JPY 637 million in Series D financing led by the Maezawa Fund, part of a larger JPY 1 billion equity and debt financing initiative. The company plans to utilize these funds to strengthen its sales and marketing efforts as well as expand its business operations. Future initiatives include the launch of new products aimed at enhancing urinary health and expanding into new markets beyond Japan.

## Funding rounds

- Series D, Mar 17, 2023, $4.8M — Maezawa Fund
- Series B, Jan 1, 2019, $9.3M — JMTC Capital
- Series A, Jul 5, 2016, $4M — Daiwa Corporate Investment, Mizuho Capital, SBI Investment, Revamp Corporation, iSGS Investment Works

## Investors

- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series A
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series A
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series A
- Revamp Corporation — Series A
- iSGS Investment Works (https://capitalatlas.ai/funds/isgs-investment-works) — Series A
- JMTC Capital (https://capitalatlas.ai/funds/jmtc-capital) — Series B
- Maezawa Fund (https://capitalatlas.ai/funds/maezawa-fund) — Series D